Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
Public ClinicalTrials.gov record NCT01369199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01369199
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- Entecavir and peginterferon Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2012
- Primary completion
- Feb 13, 2017
- Completion
- Feb 13, 2017
- Last update posted
- May 25, 2022
2012 – 2017
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| NIH Clinical Center | Bethesda | Maryland | 20892 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| University of Minnesota | Minneapolis | Minnesota | 55446 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Saint Louis University | St Louis | Missouri | 63104 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23498 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Washington Medical Center | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01369199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01369199 live on ClinicalTrials.gov.